Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

17. September 2014 16:00 ET | Quelle: ZS Pharma

ZS Pharma to Present at the 21st Annual BioCentury NewsMakers Conference

COPPELL, Texas, Sept. 17, 2014 (GLOBE NEWSWIRE) -- ZS Pharma (Nasdaq:ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today...
15. September 2014 18:30 ET | Quelle: ZS Pharma

ZS Pharma Presents New Data From ZS003 a Two Week Phase 3 Trial Demonstrating That ZS-9 Prevented Recurrence of Hyperkalemia in Heart Failure Patients on RAASi

COPPELL, Texas, Sept. 15, 2014 (GLOBE NEWSWIRE) -- ZS Pharma (Nasdaq:ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today...
11. September 2014 08:00 ET | Quelle: ZS Pharma

ZS Pharma to Present Data From Phase 3 Trial of ZS-9 in Late-Breaking Session at Heart Failure Society of America 18th Annual Scientific Meeting

COPPELL, Texas, Sept. 11, 2014 (GLOBE NEWSWIRE) -- ZS Pharma (Nasdaq:ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today...
26. August 2014 08:30 ET | Quelle: ZS Pharma

ZS Pharma to Present Late-Breaking Abstract Data from Phase 3 Trial of ZS-9 in State of the Art and Featured Research Session Oral Presentation at European Society of Cardiology (ESC) Congress

COPPELL, Texas, Aug. 26, 2014 (GLOBE NEWSWIRE) -- ZS Pharma (Nasdaq:ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today...
14. August 2014 16:30 ET | Quelle: ZS Pharma

ZS Pharma Announces Second Quarter 2014 Financial Results

COPPELL, Texas, Aug. 14, 2014 (GLOBE NEWSWIRE) -- ZS Pharma, Inc. (Nasdaq:ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders,...
17. Juli 2014 08:00 ET | Quelle: ZS Pharma

ZS Pharma Secures $20 Million in Debt Financing

COPPELL, Texas, July 17, 2014 (GLOBE NEWSWIRE) -- ZS Pharma (Nasdaq:ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today...
14. Juli 2014 16:00 ET | Quelle: ZS Pharma

ZS Pharma Completes Patient Enrollment in ZS004, Its Second Phase 3 Study of ZS-9 in Patients With Hyperkalemia

COPPELL, Texas, July 14, 2014 (GLOBE NEWSWIRE) -- ZS Pharma (Nasdaq:ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders,...
08. Juli 2014 08:00 ET | Quelle: ZS Pharma

ZS Pharma Announces Allowance of Two U.S. Patent Applications for ZS-9

COPPELL, Texas, July 8, 2014 (GLOBE NEWSWIRE) -- ZS Pharma, a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, announced today that it...

Vorherige Seite